

Cipla, SIGA Technologies collaborate to deliver access to novel AMR drugs

23 March 2021 | News

This partnership provides an opportunity for the US government agencies such as BARDA to advance preparation and health security programme initiatives



Cipla Therapeutics and SIGA Technologies, Inc, a commercial-stage pharmaceutical company focused on the health security market have announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats.

“The strategic collaboration between Cipla and SIGA will provide the Biomedical Advanced Research and Development Authority (BARDA), a US Department of Health and Human Services (HHS) department, with solutions for its biothreat and public health needs,” said Garrett Ingram, CEO, Cipla Therapeutics.

“We are thrilled to have teamed up with Cipla to tackle the very important public health challenge of Antimicrobial resistance (AMR),” said Phil Gomez, CEO, SIGA. “Our longtime partner BARDA has recognised this as a critical issue, for not only public health, but biothreats as well. With our drug development expertise under the animal rule and government contracting expertise, and Cipla’s novel antibiotic products and extensive manufacturing capabilities, we are confident that together we are ideally-suited to provide innovative solutions to BARDA and other government customers.”

This partnership provides an opportunity for the US government agencies such as BARDA to advance preparation and health security programme initiatives with the novel antibiotic ZEMDRI® (Plazomicin injection) owned and marketed by Cipla in the US, while working through a known partner in SIGA, an entity with deep expertise in USG contracting and BARDA’s hands-on approach to advanced development.